GlassScriptPhysician profile
Dana B Brown
NPI 1306809439
$21,396.79
in general payments reported to CMS, 2019-2025
58 companies · $3,560 in 2025
The $3,560 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,019 · 2020: $2,791 · 2021: $3,167 · 2022: $3,050 · 2023: $2,766 · 2024: $3,044 · 2025: $3,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,252 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,251.74 |
| Education | $117.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,408.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,317.09 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,979.74 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $1,869.00 | 2019-2025 | |
| Lilly USA, LLC | $1,440.58 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Amgen INC. | $1,181.55 | 2019-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $1,005.68 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $799.44 | 2019-2023 | |
| Glaxosmithkline, LLC. | $749.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $613.97 | 2019-2025 | Jardiance, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $590.05 | 2021-2025 | Rexulti |
| Allergan, INC. | $577.92 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $456.74 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $432.46 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $389.66 | 2019-2025 | Xifaxan |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $376.00 | 2020-2023 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $347.83 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $327.22 | 2022 | |
| Lundbeck LLC | $313.71 | 2021-2025 | Rexulti |
| Amarin Pharma, INC. | $303.29 | 2019-2022 | |
| Exact Sciences Corporation | $298.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $247.47 | 2019-2025 | Zoryve |
| Abbott Laboratories | $220.85 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $220.09 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $150.03 | 2022-2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $142.54 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $135.10 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $133.51 | 2021 | |
| Portola Pharmaceuticals, LLC | $125.00 | 2019 | |
| Daiichi Sankyo INC. | $121.47 | 2020-2021 | |
| Dexcom, INC. | $112.29 | 2023-2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $80.13 | 2020-2025 | General - Pain Management |
| Philips North America LLC | $74.16 | 2024 | (Ck6) Holter |
| Edwards Lifesciences Corporation | $68.48 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| E.R. Squibb & Sons, L.L.C. | $65.75 | 2021-2024 | Eliquis |
| Mylan Specialty L.P. | $62.48 | 2020-2023 | Yupelri |
| Idorsia Pharmaceuticals US INC | $60.89 | 2022-2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $59.45 | 2024 | Fanapt |
| Currax Pharmaceuticals LLC | $58.31 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $56.20 | 2024-2025 | Opsumit, Uptravi |
| Axsome Therapeutics, INC. | $40.97 | 2024 | Auvelity |
| Alk-Abello, INC | $40.94 | 2023-2024 | Grastek, Ragwitek, Odactra |
| Horizon Therapeutics Plc | $35.93 | 2021 | |
| Watermark Medical, INC. | $29.40 | 2024 | |
| Sanofi Pasteur INC. | $28.90 | 2019-2020 | |
| Corium, LLC | $28.86 | 2023 | Azstarys |
| Arbor Pharmaceuticals, INC. | $28.00 | 2021 | |
| Amneal Pharmaceuticals LLC | $25.30 | 2024 | Unithroid |
| Sunovion Pharmaceuticals INC. | $21.84 | 2021 | |
| Ardelyx, INC. | $21.32 | 2024 | Ibsrela |
| Inspire Medical Systems, INC. | $21.26 | 2023 | Inspire |
| Genentech USA, INC. | $18.88 | 2019 | |
| Azurity Pharmaceuticals, INC. | $18.20 | 2024 | Horizant |
| Ironwood Pharmaceuticals, INC | $14.02 | 2021 | |
| Tris Pharma INC | $13.84 | 2024 | Dyanavel Xr |
| Phathom Pharmaceuticals, INC. | $13.78 | 2024 | Voquezna |
| Cequr Corporation | $11.93 | 2024 | Cequr Simplicity |
| Therapeuticsmd, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.